The FDA has approved Inlexzo (gemcitabine intravesical system) for the treatment of adult patients with BCG-unresponsive, non-muscle invasive bladder cancer with CIS with or without papillary tumors.

(HealthDay News) — Poor cardiovascular-kidney-metabolic (CKM) health is associated with an increased risk for psoriasis, especially for those with high genetic risk, according to a study published ...

An investigational factor XI inhibitor shows early promise for treating atrial fibrillation in patients with a degree of kidney impairment.

Multiparametric MRI was a game changer for prostate cancer diagnosis. Now trial findings suggest a simpler imaging protocol may be as effective.

However, BCC rates similar by College of American Pathologists and Clinical and Laboratory Standards Institute criteria.

The committee found strong evidence that glucagon-like peptide-1 (GLP-1) receptor agonists benefit people with type 2 diabetes, particularly those with heart or kidney disease, by improving glucose ...

Beyond GLP-1 RA prescriptions, chronic kidney disease (CKD) patients require comprehensive care from doctors, dietitians, & ...

Study findings support intensive blood pressure control in patients with hypertension without chronic kidney disease at baseline.

Tumors with higher stromal content may have a TME in an immune-overstimulated state, which could be a factor in their worse prognosis, the researchers suggested. Based on its associations with PD-L1 ...

As changes to Medicare Part D prescription drug coverage have taken effect with implementation of the IRA, concurrent changes in plan design have increased cost-sharing burdens for patients, data ...

Semaglutide was associated with a significantly greater reduction in MACE risk vs tirzepatide in patients with overweight/obesity and CVD.

High levels of hsCRP indicates risk in women without any of the four standard modifiable cardiovascular risk factors.